Tanox, Inc.

40 articles about Tanox, Inc.

• 

  Viela Bio Spins Out of AstraZeneca’s MedImmune with $250 Million Series A Fun...

  2/28/2018

  Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.

• Genentech, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox, Inc.

  8/2/2007

• Tanox, Inc. Reports 2007 First Quarter Results

  5/10/2007

• Tanox, Inc. Reports Fourth Quarter and Full Year 2006 Results

  3/16/2007

• Genentech, Inc. And Tanox, Inc. Receive 'Second Request' From The Federal Trade Commission

  1/29/2007

• Tanox, Inc. Stockholders Approve Merger With Genentech, Inc.

  1/16/2007

• The Day In Review: Genentech Pays $919 Million For Tanox, Inc.

  11/10/2006

• Tanox, Inc. Reports 2006 Third Quarter Results

  11/2/2006

• The Day In Review: Icahn Takes Over As ImClone Systems Incorporated Chairman

  10/25/2006

• Tanox, Inc. To Report Third Quarter 2006 Financial Results, Host Conference Call For Investors Nov. 2

  10/25/2006

• Tanox, Inc. Initiates Phase 1 Clinical Trial Evaluating TNX-650 For Treatment Of Asthma

  10/25/2006

• Tanox, Inc. To Present At UBS Warburg Global Life Sciences Conference

  9/14/2006

• Tanox, Inc. Release: New Data Confirm Durable Response Of TNX-355 Regimens Through 48 Weeks In Treatment-Experienced HIV Patients

  8/17/2006

• Tanox, Inc. Reports 2006 Second Quarter Results

  8/8/2006

• Tanox, Inc. Conducts Meeting With FDA Regarding Its HIV/AIDS Antibody, TNX-355

  8/4/2006

• Tanox, Inc. To Report Second Quarter 2006 Financial Results, Host Conference Call For Investors Aug. 8

  7/18/2006

• Tanox, Inc. Release: Results Of TNX-355 Combination Study Published In Antimicrobial Agents And Chemotherapy

  6/1/2006

• First Patient Dosed In Phase 1 Trial Of Tanox, Inc.'s TNX-650

  5/23/2006

• Tanox, Inc. Reports 48-Week Results From TNX-355 Phase 2 Clinical Trial

  5/2/2006

• Tanox, Inc. Reports 2006 First Quarter Results

  5/2/2006